47 results about "Pancreatic glucagon" patented technology

The invention discloses a preparing method of glucagons example peptide -2(GLP-2) through restructuring, which can prepare a good deal of stable biological active GLP-2 peptide. This invention also discloses a usage to prepare drugs for accelerate growth of intestine mucosa with GLP-2 peptide.

The invention relates to a novel molecular drug structure of recombinant human serum albumin / pancreatic glucagon peptide fusion protein capable of obviously reducing blood sugar content in blood and having continuous effect: rGLP-12 / HSA / GLP-12. Especially, the invention uses a genetic engineering technology for constructing the engineered yeast strain to express the produced recombinant fusion protein. The recombinant fusion protein has the advantages that 1) blood sugar content in the blood is reduced, body weight is reduced, and the recombinant fusion protein is used for treating diabetes and cardiovascular disease; 2) life of pancreatic glucagon peptide is greatly prolonged in vitro and vivo, so that the recombinant fusion protein has maximum stability in the blood and can be continuously effected on the blood sugar control; and 3) saccharomycetes can be used for realizing low-cost large-scale production and preparation process.

Long-acting co-agonists of the glucagon and GLP-1 receptors are described.

The invention describes a novel stable preparation of a recombinant human pancreatic glucagon-like peptide-1 analogue fusion protein. The medicinal preparation can be used for treating diabetes and related diseases.

The invention relates to application of a pancreatic GnRH receptor function regulator to preparation of drugs used for treating type 2 diabetes. According to the invention, pancreases with normal glucose concentration and pancreases with high-concentration glucose for simulating diabetes are subjected to perfusion of GnRH and a pancreatic GnRH receptor, and results show that pancreatic GnRH with a certain concentration has important regulating effect on the secretion time phase of main hormones of pancreatic islets, i.e., insulin and pancreatic glucagon and that a perfusion solution with certain-concentration GnRH does not inhibit the secretion of pancreatic glucagon, stimulates the secretion of pancreatic glucagon instead and leads to delay of the secretion peak of insulin. Thus, a theoretical and experimental foundation is provided for preparation of drugs for regulating the secretion time phase of insular hormones in virtue of pancreatic GnRH and regulating substances for the receptor approach of pancreatic GnRH and further for preparation of drugs used for restoring inhibition of high glucose on pancreatic glucagon in virtue of pancreatic GnRH and the receptor approach thereof.

The present invention provides an oil-in-water nanoemulsion containing glucagon, an oily phase, and an aqueous phase, wherein the glucagon is physically and chemically stable and the nanoemulsion is suitable for administration by manual injection or by a pump to treat hypoglycemia.

The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.

The present invention provides a compound of Formula (I)or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

The present invention relates to glucagon receptor agonists and their medical use, for example for the treatment of severe hypoglycemia. Exendin-4 analogs are provided that potently and selectively activate the glucagon receptor and exhibit higher solubility at near neutral pH and enhanced in solution compared to native glucagon chemical stability. The analog has the artificial amino acid 4-thiazolealanine at position 1. This resulted in a higher selectivity for the glucagon receptor over the GLP1 receptor when compared to each other for the same compounds differing only in position 1 (Tza instead of His at position 1). The present invention provides highly selective glucagon receptor agonists.

The present invention discloses a FGF21 fusion protein, which comprises: (1): a glucagon-like polypeptide 1 (GLP-1) variant of the amino acid sequence shown in SEQ ID NO: 4, SEQ ID NO: The connecting peptide of the amino acid sequence shown in 6, the Fc part of the human IgG4 variant antibody of the amino acid sequence shown in SEQ ID NO: 8, and the fibroblast growth factor 21 (FGF21) of the amino acid sequence shown in SEQ ID NO: 10 Variant; or (2): a fusion protein derived from (1) having the amino acid sequence in (1) substituted, deleted or added with one or several amino acids and having FGF21 fusion protein activity. The invention also discloses a method for inhibiting the degradation of the FGF21 fusion protein, which comprises adding a C1 protease inhibitor to the culture medium. The method of the present invention can effectively inhibit the degradation of FGF21 fusion protein.

Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery. Current therapeutic options have suboptimal efficacy. Small doses of stable liquid glucagon canbe used to treat or prevent post-bariatric hypoglycemia.